CA2149055A1 - Compositions antitumorales contenant des derives du taxane - Google Patents

Compositions antitumorales contenant des derives du taxane

Info

Publication number
CA2149055A1
CA2149055A1 CA002149055A CA2149055A CA2149055A1 CA 2149055 A1 CA2149055 A1 CA 2149055A1 CA 002149055 A CA002149055 A CA 002149055A CA 2149055 A CA2149055 A CA 2149055A CA 2149055 A1 CA2149055 A1 CA 2149055A1
Authority
CA
Canada
Prior art keywords
esp
derivatives
antitumoral
synthetic
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002149055A
Other languages
English (en)
Other versions
CA2149055C (fr
Inventor
Marie-Christine Bissery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Marie-Christine Bissery
Rhone-Poulenc Rorer S.A.
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9435406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2149055(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Marie-Christine Bissery, Rhone-Poulenc Rorer S.A., Aventis Pharma S.A. filed Critical Marie-Christine Bissery
Publication of CA2149055A1 publication Critical patent/CA2149055A1/fr
Application granted granted Critical
Publication of CA2149055C publication Critical patent/CA2149055C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)

Abstract

2149055 9410995 Combinaisons antitumorales constituées de taxol ou de Taxotère ou de leurs analogues associés à au moins une substance thérapeutiquement utile dans le traitement des maladies néoplastiques.
CA002149055A 1992-11-10 1993-11-08 Compositions antitumorales contenant des derives du taxane Expired - Lifetime CA2149055C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9213525A FR2697752B1 (fr) 1992-11-10 1992-11-10 Compositions antitumorales contenant des dérivés du taxane.
FR92/13525 1992-11-10
PCT/FR1993/001096 WO1994010995A1 (fr) 1992-11-10 1993-11-08 Compositions antitumorales contenant des derives du taxane

Publications (2)

Publication Number Publication Date
CA2149055A1 true CA2149055A1 (fr) 1994-05-26
CA2149055C CA2149055C (fr) 2003-01-07

Family

ID=9435406

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002149055A Expired - Lifetime CA2149055C (fr) 1992-11-10 1993-11-08 Compositions antitumorales contenant des derives du taxane

Country Status (25)

Country Link
US (13) US5728687A (fr)
EP (4) EP0827745B1 (fr)
JP (1) JP3974938B2 (fr)
KR (2) KR100334051B1 (fr)
AT (2) ATE205083T1 (fr)
AU (1) AU680845B2 (fr)
CA (1) CA2149055C (fr)
CZ (2) CZ288033B6 (fr)
DE (2) DE69318033T2 (fr)
DK (2) DK0667771T3 (fr)
ES (2) ES2163076T3 (fr)
FI (1) FI952248A0 (fr)
FR (1) FR2697752B1 (fr)
GR (2) GR3026666T3 (fr)
HU (1) HU223773B1 (fr)
MX (1) MX9306924A (fr)
NO (1) NO315027B1 (fr)
NZ (1) NZ257585A (fr)
PL (1) PL173951B1 (fr)
PT (1) PT827745E (fr)
RU (1) RU2131250C1 (fr)
SK (1) SK282867B6 (fr)
TW (1) TW386877B (fr)
WO (1) WO1994010995A1 (fr)
ZA (1) ZA938182B (fr)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6011069A (en) * 1995-12-26 2000-01-04 Nisshin Flour Milling Co., Ltd. Multidrug resistance inhibitors
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6667053B1 (en) * 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
AU2195297A (en) * 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US5811452A (en) * 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6740497B2 (en) * 1998-03-06 2004-05-25 The Regents Of The University Of California Method and apparatus for detecting cancerous cells using molecules that change electrophoretic mobility
US6335201B1 (en) * 1998-03-06 2002-01-01 The Regents Of The University Of California Method and apparatus for detecting enzymatic activity using molecules that change electrophoretic mobility
AU750010B2 (en) * 1998-03-27 2002-07-11 Pharmacia & Upjohn Company Methods to potentiate intravenous estramustine phosphate
US6849616B1 (en) 1998-03-27 2005-02-01 Pharmacia Italia S.P.A. Methods to potentiate intravenous estramustine phosphate
CN1140272C (zh) * 1998-04-03 2004-03-03 味之素株式会社 抗肿瘤剂
WO1999056742A1 (fr) * 1998-05-04 1999-11-11 Auckland Uniservices Limited Traitement chimiotherapique
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
WO2000006134A2 (fr) * 1998-07-30 2000-02-10 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Utilisation de l-carnitine et de ses derives alkanoyl dans la preparation de medicaments a action anticancereuse
GB9904386D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US20050222246A1 (en) * 1999-04-14 2005-10-06 Li Chiang J Beta-lapachone is a broad spectrum anti-cancer agent
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
US6737240B1 (en) * 1999-05-25 2004-05-18 Rigel Pharmaceuticals, Inc. Methods of screening for a multi-drug resistance conferring peptide
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DK1189634T3 (da) * 1999-06-25 2007-06-25 Genentech Inc Behandling af prostatacancer med anti-ErbB2-antistoffer
CN100340575C (zh) * 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
DK1210115T3 (da) * 1999-08-27 2009-11-30 Genentech Inc Doseringer til behandling med anti-ErB2-antistoffer
CA2385528C (fr) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
HUP0200759A3 (en) * 2000-02-02 2002-10-28 Univ Florida State Res Found C10 carbonate substituted taxanes as antitumor agents and pharmaceutical compositions containing them and their use
US6362217B2 (en) * 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
CA2747325A1 (fr) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Proteines fusionnees a l'albumine
AU2001259271A1 (en) * 2000-04-28 2001-11-12 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
PL217410B1 (pl) * 2000-05-19 2014-07-31 Genentech Inc Zastosowanie antagonisty ErbB, antagonista ErbB do zastosowania w metodzie leczenia raka i sposób identyfikacji pacjenta skłonnego do korzystnej odpowiedzi na antagonistę ErbB przy leczeniu raka
US6541509B2 (en) * 2000-09-15 2003-04-01 Albert Einstein College Of Medicine Of Yeshiva University Method for treating neoplasia using combination chemotherapy
CA2422964A1 (fr) * 2000-09-22 2002-03-28 Bristol Myers Squibb Company Procede de reduction de la toxicite de chimiotherapies combinees
SK287901B6 (sk) * 2000-11-06 2012-03-02 Pharma Mar, S. A. Use of Ecteinascidin 743 for preparation of medicament for effective antitumor treatment
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
RU2178702C1 (ru) * 2001-02-21 2002-01-27 Общество с ограниченной ответственностью "Нобель" Антираковое средство
US6703400B2 (en) * 2001-02-23 2004-03-09 Schering Corporation Methods for treating multidrug resistance
KR20030081496A (ko) * 2001-03-06 2003-10-17 브리스톨-마이어스 스큅 컴퍼니 테가푸르, 우라실, 폴린산, 파클리탁셀 및 카르보플라틴투여를 통한 종양 치료 방법 및 이들의 투여 형태
ATE554756T1 (de) * 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
EP1372571A4 (fr) * 2001-03-20 2006-06-07 New Century Pharmaceuticals Procede et compositions permettant d'optimiser la stabilite du sang et des tissus conferee par la camptothecine et par d'autres composes therapeutiques liant l'albumine
US20020182204A1 (en) * 2001-03-23 2002-12-05 Marie-Christine Bissery Combination of a taxane and a cyclin-dependent kinase
US20030143191A1 (en) * 2001-05-25 2003-07-31 Adam Bell Chemokine beta-1 fusion proteins
US6924312B2 (en) 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
EP1293205A1 (fr) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Acide valproique et ses dérivés pour la polythérapie du cancer humain et pour le traitement de la métastase de tumeurs et de la maladie residuelle imperceptible
US20040191218A1 (en) * 2001-09-26 2004-09-30 Emlen James W Pharmaceutical compositions and methods for treating cancer
WO2003039571A1 (fr) * 2001-10-19 2003-05-15 Pharmamar S.A. Utilisation amelioree de compose anti-tumoral dans le traitement des cancers
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
EP1463752A4 (fr) * 2001-12-21 2005-07-13 Human Genome Sciences Inc Proteines de fusion d'albumine
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US6816571B2 (en) * 2002-02-06 2004-11-09 L-3 Communications Security And Detection Systems Corporation Delaware Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
US7426479B2 (en) * 2002-03-12 2008-09-16 Ncr Corporation Customer activity data system and method
US6593334B1 (en) * 2002-05-02 2003-07-15 The University Of North Carolina At Chapel Hill Camptothecin-taxoid conjugates as antimitotic and antitumor agents
ME00055B (me) * 2002-05-17 2010-10-10 Aventis Pharma Sa Primjena docetaksel/doksorubicin/ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika
CN1678296A (zh) * 2002-07-30 2005-10-05 卡里凯昂公司 依泽替米贝的组合物和治疗胆固醇有关的良性与恶性肿瘤的方法
US20040258685A1 (en) * 2002-11-21 2004-12-23 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
US20040229931A1 (en) * 2003-04-30 2004-11-18 Aventis Pharma S. A. 1-Aryl-3-(indol-5-yl) prop-2-en-1-ones, compositions containing them and use
EP1663153A4 (fr) * 2003-05-20 2011-01-05 Aronex Pharmaceuticals Inc Chimiotherapie combinee comprenant un complexe de platine liposomal
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
RS50692B (sr) * 2003-11-13 2010-06-30 Pharma Mar S.A.U. Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
US20050192247A1 (en) * 2004-02-23 2005-09-01 Li Chiang J. Method of treating cancers
MXPA06009547A (es) * 2004-02-23 2007-01-26 Dana Farber Cancer Inst Inc Metodo para tratar el crecimiento celular anormal usando inhibidores de c-met y m-tor.
BRPI0512526A (pt) 2004-06-23 2008-03-11 Synta Pharmaceuticals Corp composto, composição farmacêutica, método para tratar um paciente com cáncer e método para preparar um di-sal de bis(tio-hidrazida amida)
JP2008514688A (ja) * 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
CA2582452C (fr) * 2004-10-26 2010-09-07 Erard Gilles Doxorubicine liposomale pegylee en combinaison avec l'ecteinascidine 743
BRPI0517238B1 (pt) * 2004-10-29 2021-11-09 Pharma Mar, S.A. Composições que compreendem ecteinascidina e um dissacarídeo, método para produzir um frasco que contém a referida composição e para preparar uma solução para infusão intravenosa e uso da referida solução
WO2006055747A2 (fr) 2004-11-19 2006-05-26 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) pour augmenter l'expression de hsp70
CN101083998A (zh) * 2004-11-22 2007-12-05 王者制药研究发展有限公司 用腺苷a3受体激动剂强化治疗hif－1介导的病症
CA3054535A1 (fr) * 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinaisons et modes d'administration d'agents therapeutiques et de therapie combinee
DK1866339T3 (da) * 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
BRPI0610219A2 (pt) 2005-04-15 2010-06-08 Synta Pharmaceuticals Corp métodos de tratamento de um ser humano com cáncer e composição de farmacêutica
CA2607890A1 (fr) 2005-05-16 2006-11-23 Synta Pharmaceuticals Corp. Synthese de sels de bis(thio-hydrazide amide)
US7879816B2 (en) * 2005-06-07 2011-02-01 Yale University Methods of treating cancer and other conditions or disease states using LFMAU and LDT
AU2006279891B2 (en) 2005-08-16 2010-03-11 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
US20070172844A1 (en) * 2005-09-28 2007-07-26 University Of South Florida Individualized cancer treatments
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
PE20070763A1 (es) * 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
EP1948179A1 (fr) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Derives de quinazoline pour le traitement des affections cancereuses
AU2007223012A1 (en) * 2006-03-08 2007-09-13 University Of Maryland, Baltimore Inhibition of microtubule protrusion in cancer cells
WO2007139930A2 (fr) * 2006-05-26 2007-12-06 Bayer Healthcare Llc Associations de médicaments comportant des urées de diaryle substituées pour le traitement du cancer
JP2010501562A (ja) 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 増殖性障害を治療するための化合物
WO2008027445A2 (fr) 2006-08-31 2008-03-06 Synta Pharmaceuticals Corp. Combinaisons de bis(thio-hydrazide amides) traitant le cancer
TW200829543A (en) 2006-09-15 2008-07-16 Synta Pharmaceuticals Corp Purification of bis(thiohydrazide amides)
RU2492864C2 (ru) * 2006-09-18 2013-09-20 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения рака, несущего мутации egfr
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
US20090093538A1 (en) * 2007-01-03 2009-04-09 Synta Pharmaceuticals Corp Method for treating cancer
US8591886B2 (en) * 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2201141A1 (fr) * 2007-10-19 2010-06-30 Pharma Mar S.A. Marqueurs moléculaires pronostiques pour le traitement par et-743
HUE044629T2 (hu) 2009-07-06 2019-11-28 Boehringer Ingelheim Int Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására
WO2013174403A1 (fr) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
TW202214691A (zh) 2014-03-21 2022-04-16 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
US9937261B2 (en) 2014-06-09 2018-04-10 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin C and radiotherapy
MX2018015272A (es) 2016-06-08 2019-08-12 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
CA3027033A1 (fr) 2016-06-08 2017-12-14 Abbvie Inc. Anticorps anti-cd98 et conjugues anticorps-medicament
LT3458479T (lt) 2016-06-08 2021-02-25 Abbvie Inc. Anti-b7-h3 antikūnai ir antikūnų vaisto konjugatai
BR112018075653A2 (pt) 2016-06-08 2019-08-27 Abbvie Inc anticorpos anti-b7-h3 e conjugados anticorpo fármaco
JP2019521973A (ja) 2016-06-08 2019-08-08 アッヴィ・インコーポレイテッド 抗ｂｈ７−ｈ３抗体及び抗体薬物コンジュゲート
RU2680834C1 (ru) * 2018-05-23 2019-02-28 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Противоопухолевая композиция доксорубицина с ингибитором АТФ-зависимых обратных транспортеров клеток
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206221A (en) 1979-01-03 1980-06-03 The United States Of America As Represented By The Secretary Of Agriculture Cephalomannine and its use in treating leukemic tumors
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en) * 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
FR2623089B1 (fr) * 1987-11-13 1990-04-27 Pf Medicament Composition pharmaceutique pour l'administration parenterale de navelbine
GB8806224D0 (en) 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
US5015744A (en) * 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
AU2005692A (en) * 1991-05-08 1992-12-21 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
US5284864A (en) * 1991-09-23 1994-02-08 Florida State University Butenyl substituted taxanes and pharmaceutical compositions containing them
US5229526A (en) * 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5262409A (en) * 1991-10-11 1993-11-16 Fred Hutchinson Cancer Research Center Binary tumor therapy
US5294737A (en) * 1992-02-27 1994-03-15 The Research Foundation State University Of New York Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom
US5254580A (en) 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5495501A (en) * 1992-09-02 1996-02-27 Fujitsu Limited Communication system including a digital roll-off filter
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5814658A (en) 1992-12-09 1998-09-29 Rhone-Poulenc Rorer S.A. Taxoids, their preparation and pharmaceutical compositions containing them
IL107950A (en) 1992-12-15 2001-04-30 Upjohn Co b 7, b 8 - Matano - Taxols, their preparation and pharmaceutical preparations against malignant tumors containing them
US6441026B1 (en) 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
DE69330722T2 (de) 1993-12-03 2002-07-11 Infineum Usa Lp Carbonylgruppen enthaltende verbindungen
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP0982028A1 (fr) 1998-08-20 2000-03-01 Aventis Pharma S.A. Nouvelle utilisation de dérivés de taxoides
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
US7696923B2 (en) * 2005-02-03 2010-04-13 Mexens Intellectual Property Holding Llc System and method for determining geographic location of wireless computing devices

Also Published As

Publication number Publication date
FR2697752A1 (fr) 1994-05-13
US5728687A (en) 1998-03-17
US20040152642A1 (en) 2004-08-05
US20110263522A1 (en) 2011-10-27
NO951327D0 (no) 1995-04-05
CZ288033B6 (cs) 2001-04-11
RU2131250C1 (ru) 1999-06-10
JPH08503205A (ja) 1996-04-09
US7989489B2 (en) 2011-08-02
US20020197245A1 (en) 2002-12-26
GR3036537T3 (en) 2001-12-31
DE69318033T2 (de) 1998-10-22
US8101652B2 (en) 2012-01-24
EP0827745A1 (fr) 1998-03-11
TW386877B (en) 2000-04-11
GR3026666T3 (en) 1998-07-31
US20040152643A1 (en) 2004-08-05
EP1093811A1 (fr) 2001-04-25
ATE205083T1 (de) 2001-09-15
KR100334051B1 (ko) 2002-09-04
KR950703945A (ko) 1995-11-17
US20050226940A1 (en) 2005-10-13
MX9306924A (es) 1994-05-31
ES2114620T3 (es) 1998-06-01
AU680845B2 (en) 1997-08-14
DE69330724D1 (de) 2001-10-11
CZ290120B6 (cs) 2002-06-12
DE69318033D1 (de) 1998-05-20
FI952248A (fi) 1995-05-09
KR20030096445A (ko) 2003-12-31
EP0667771B1 (fr) 1998-04-15
ES2163076T3 (es) 2002-01-16
US20040152673A1 (en) 2004-08-05
PL173951B1 (pl) 1998-05-29
SK282867B6 (sk) 2003-01-09
CA2149055C (fr) 2003-01-07
PL308902A1 (en) 1995-09-04
DE69330724T2 (de) 2002-07-11
US20040152644A1 (en) 2004-08-05
ATE165002T1 (de) 1998-05-15
SK59595A3 (en) 1996-05-08
PT827745E (pt) 2002-02-28
ZA938182B (en) 1994-06-09
EP0827745B1 (fr) 2001-09-05
US20040157786A1 (en) 2004-08-12
NO951327L (no) 1995-04-05
CZ119395A3 (en) 1995-10-18
WO1994010995A1 (fr) 1994-05-26
EP0667771A1 (fr) 1995-08-23
DK0667771T3 (da) 1998-10-07
US8124650B2 (en) 2012-02-28
FI952248A0 (fi) 1995-05-09
HU223773B1 (hu) 2005-01-28
JP3974938B2 (ja) 2007-09-12
DK0827745T3 (da) 2001-11-19
FR2697752B1 (fr) 1995-04-14
EP1295597A1 (fr) 2003-03-26
US7994212B2 (en) 2011-08-09
AU5425394A (en) 1994-06-08
NZ257585A (en) 1996-06-25
US5908835A (en) 1999-06-01
NO315027B1 (no) 2003-06-30
HUT72499A (en) 1996-05-28
US6239167B1 (en) 2001-05-29
US20040013660A1 (en) 2004-01-22
HU9501372D0 (en) 1995-06-28
US6214863B1 (en) 2001-04-10

Similar Documents

Publication Publication Date Title
AU680845B2 (en) Antitumour compositions containing taxane derivatives
RU95112842A (ru) Противоопухолевая композиция, содержащая производные таксана
WO2003086279A3 (fr) Inhibiteurs de l'activite de akt
BG102879A (en) Carbolin derivatives
HK1155944A1 (en) W-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
CA2480800A1 (fr) Inhibiteurs de l'activite akt
CA2315647A1 (fr) Inhibition de l'activite de p38 kinase au moyen d'urees heterocycliques aryle et heteroaryle substituees
WO2001047928A3 (fr) Nouveaux imidazo[1,3,5]triazinones et leur utilisation
AU3939893A (en) Induction of somatic embryogenesis in (taxus), and the production of taxane-ring containing alkaloids therefrom
GR930300141T1 (en) Taxane derivatives, their preparation and use in oncology
AU5425794A (en) Process for the preparation of taxane derivatives, novel taxanes so obtained and antitumour and antileukaemia compositions containing same
GEP20032914B (en) Derivatives of 1,3,4-Oxadiazolone
WO1988008842A3 (fr) 2-ACYLPYRIDIN-alpha-(N)-HETARYLHYDRAZONES SUBSTITUEES ET MEDICAMENTS CONTENANT CELLES-CI
AU5857899A (en) Use of tgf-beta inhibitors for treating cerebral disorders
NO955235D0 (no) Fremgangsmåte og virkestoff for forhindring av mikrobiell vekst på overflater, samt masse for overflatebelegging eller- foredling
CA2360676A1 (fr) Procede pour traiter les patients atteints de l'acne par l'administration d'inhibiteurs pde cgmp
CA2156908A1 (fr) Derives c9 du taxane; compositions pharmaceutiques a base de ces derives

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20131108